Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF). reported that, in addition to its potential lead new chemical entity (NCE) candidate MSP-4018, it has identified two additional pipeline opportunities from its Family 4 compounds MSP-4019 and MSP-4020.
In preclinical studies, the company said both compounds demonstrated strong efficacy and an improved safety profile in comparison to 5-MeO-DMT and parent compounds.
“Our Family 4 compounds leverage Mindset’s conjugate amplification technology, which has enabled us to rapidly generate clinical candidates that improve upon first-generation psychedelic efficacy and safety,” said Mindset CEO James Lanthier in a statement. “Using a platform approach to advance our differentiated compounds into the clinic, we aim to broaden patient access for mental health sufferers and provide solutions to address a range of patient needs."
READ: Mindset Pharma added to NYSE-listed AdvisorShares Psychedelics ETF
Joseph Araujo, chief scientific officer of Mindset, added: “The preclinical results of MSP-4019 and MSP-4020 demonstrated strong efficacy through a mouse head twitch assay and an improved safety profile at a range of doses up to 30 mg/kg. Our next-generation compounds showed no signs of 5-HT syndrome, a serious potential health risk associated with first-generation drugs, 5-MeO-DMT and DMT. We will continue to validate our novel compounds through translational models as we select one or more lead drug candidates from our Family 4 NCEs to advance into the clinic.”
Mindset’s Family 4 compounds are DMT and 5-MeO-DMT-inspired novel drug candidates that offer a broad range of pharmacological diversity suitable for in-clinic settings.
The company said it has run a battery of specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates as it progresses towards human clinical trials.
Mindset is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
The company was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham